Research teams link response to Iressa to mutations in EGF receptor.
SPOREs hammer out research agenda, seek $50,000 from NCI for further tissue analysis.
Dramatic responses to Iressa prompted further bench research. Results have limited clinical relevance, for now, but findings may explain failure of INTACT studies.
NCI blocked groups from phase III Iressa studies.
Also in this 8-page issue: Amgen names PhRMA executive Rodger Currie vice president for government affairs.
Robert Hall appointed government relations director for National Coalition for Cancer Survivorship.
Funding opportunities listed.
April issue of Business & Regulatory Report included (8 additional pages).
Trending Stories
- As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.” - At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
